What is the recommended dosing for Focalin ER (Dexmethylphenidate) in a patient with Attention Deficit Hyperactivity Disorder (ADHD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Focalin ER Dosing for ADHD

Starting Dose

For patients new to methylphenidate, start Focalin ER at 5 mg once daily in the morning for pediatric patients (ages 6-17) and 10 mg once daily for adults. 1

  • For patients currently taking immediate-release methylphenidate, convert to Focalin ER at half (1/2) the total daily methylphenidate dose 1
  • For patients already on immediate-release dexmethylphenidate, give the same total daily dose as Focalin ER 1
  • Administer once daily in the morning, with or without food 1

Titration Schedule

Increase the dose weekly in increments of 5 mg for pediatric patients and 10 mg for adults until optimal response is achieved or side effects emerge. 1

  • The bimodal release profile mimics two doses of immediate-release dexmethylphenidate given 4 hours apart, providing symptom control throughout the day 2
  • Monitor response using standardized ADHD rating scales from teachers and parents for children, or from patients and significant others for adults 3
  • Maintain weekly contact during initial titration, which typically requires 2-4 weeks to reach optimal dosing 4

Maximum Doses

  • Pediatric patients (ages 6-17): Maximum 30 mg daily 1
  • Adults: Maximum 40 mg daily 1

Efficacy Profile

Focalin ER demonstrates rapid onset and prolonged duration of action:

  • Significant improvement in ADHD symptoms begins as early as 0.5 hours after administration 2
  • Duration of effect extends 11-12 hours post-dose, covering the full school or work day 2, 5
  • All three fixed doses (10,20, and 30 mg) showed significantly greater efficacy than placebo across multiple settings (school, home, clinic) 5
  • Average titrated dose of 18.25 mg/day dexmethylphenidate provides equivalent efficacy to 32.14 mg/day of racemic methylphenidate, demonstrating 2:1 potency 6

Administration Options

  • Capsules may be swallowed whole or opened and sprinkled on applesauce for patients unable to swallow capsules 1
  • This flexibility is particularly useful for pediatric patients who have difficulty with pill swallowing 2

Monitoring Requirements

Systematically assess both therapeutic response and side effects at each visit:

  • Monitor blood pressure and pulse regularly 4
  • Track height and weight at each visit, as growth suppression can occur with stimulants 4, 1
  • Screen for common side effects including decreased appetite, headache, anxiety, dyspepsia, and insomnia 1
  • After stabilization, schedule follow-up appointments at least monthly 4

Clinical Considerations

  • Dexmethylphenidate contains only the d-threo-enantiomer (active isomer) of methylphenidate, allowing for lower total drug load while maintaining efficacy 6, 7
  • In open-label titration studies, 82% of patients achieved "much" or "very much improved" ratings on Clinical Global Impression scales 8
  • The once-daily formulation eliminates the need for midday dosing at school, improving adherence and reducing stigma 2
  • Discontinuation rates due to adverse events are low, with only 5 of 89 patients discontinuing in clinical trials 8

Common Pitfalls to Avoid

  • Do not start at excessively high doses, as this leads to unnecessary side effects and decreased medication adherence 4
  • Do not use weight-adjusted dosing for titration, as this method is problematic in practice and not uniformly supported by research 3
  • Do not assume the medication has failed if initial doses are inadequate—systematic titration through the full dose range is essential, as 70-80% of patients respond when properly titrated 4
  • Never use concurrently with MAO inhibitors or within 14 days of MAOI discontinuation due to risk of hypertensive crisis 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.